{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:09:27Z","timestamp":1789412967108,"version":"build-2803163510"},"reference-count":115,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010272","name":"Zarqa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.seminoncol.2025.152438","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:12:15Z","timestamp":1762272735000},"page":"152438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genome editing of immune checkpoints: CRISPR-mediated PD-1 inhibition in cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Suleiman Ibrahim","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Kareem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asokan","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MM","family":"Rekha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid S.","family":"Jabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PriyaPriyadarshini","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"AlKhafaje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WesamR","family":"Kadhum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kattela","family":"Chennakesavulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2025.152438_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1265299","article-title":"Progress of research on PD-1\/PD-L1 in leukemia","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0002","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10238-022-00873-6","article-title":"Anti-PD-1\/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma","volume":"23","author":"Chen","year":"2023","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101527","article-title":"PD-1\/PD-L1 blockade accelerates the progression of atherosclerosis in cancer patients","volume":"48","author":"Dong","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0004","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0005","article-title":"The PD-1\/PD-L1 pathway: a perspective on comparative immuno-oncology","volume":"12","author":"Sch\u00f6niger","year":"2022","journal-title":"Animals (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0006","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000464353","article-title":"PD-1\/PD-L1 pathway in breast cancer","volume":"40","author":"Sch\u00fctz","year":"2017","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1440-1681.13028","article-title":"The roles of PD-1\/PD-L1 and its signalling pathway in gastrointestinal tract cancers","volume":"46","author":"Cui","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0008","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.seminoncol.2025.152438_bib0009","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17512433.2018.1464388","article-title":"PD-1\/PD-L1 pathway inhibitors in advanced prostate cancer","volume":"11","author":"Isaacsson Velho","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0010","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225399","article-title":"Clinical PD-1\/PD-L1 blockades in combination therapies for lymphomas","volume":"15","author":"Katsuya","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0012","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41467-019-09296-6","article-title":"iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer","volume":"10","author":"Ding","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0013","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ncrna.2024.10.005","article-title":"Glycolysis regulated exosomal LINC01214 inhibited CD8(+) T cell function and induced anti-PD1 resistance in melanoma via modulating miR-4492\/PPP1R11 axis","volume":"10","author":"Ding","year":"2025","journal-title":"Noncoding RNA Res"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0014","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1021\/acsmaterialslett.4c00504","article-title":"Ferroptosis amplifier remodels redox homeostasis for enhanced cancer chemoimmunotherapy","volume":"6","author":"Zhang","year":"2024","journal-title":"ACS Mater Lett"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0040-1721451","article-title":"World-first phase I clinical trial for CRISPR-Cas9 PD-1-edited T-cells in advanced nonsmall cell lung cancer","volume":"7","author":"Liu","year":"2020","journal-title":"Glob Med Genet"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0016","series-title":"Am Soc Clin Oncol","first-page":"3050","article-title":"A phase I trial of PD-1 deficient engineered T cells with CRISPR\/Cas9 in patients with advanced non-small cell lung cancer","author":"Lu","year":"2018"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202004879","article-title":"Photo-enhanced CRISPR\/Cas9 system enables robust pd-l1 gene disruption in cancer cells and cancer stem-like cells for efficient cancer immunotherapy","volume":"16","author":"Zhao","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0018","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1021\/acs.bioconjchem.5c00001","article-title":"Tumor cell membrane biomimetic mesoporous silicon materials in combination with PD-L1 knockout achieved through the CRISPR\/Cas9 system for targeted and immunotherapeutic purposes","volume":"36","author":"Zhao","year":"2025","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119359","article-title":"Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy","volume":"218","author":"Lee","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0020","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1089\/hum.2018.048","article-title":"Synergistic antitumor effect on bladder cancer by rational combination of programmed cell death 1 blockade and CRISPR-Cas9-mediated long non-coding RNA urothelial carcinoma associated 1 knockout","volume":"29","author":"Zhen","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.23925\/1984-4840.2019v21i1a2","article-title":"Inhibition of PD-1 protein by the CRISPR-Cas9 method as antitumor therapy of non-small cell lung cancers","volume":"21","author":"Biggi","year":"2019","journal-title":"Revista da Faculdade de Ci\u00eancias M\u00e9dicas de Sorocaba"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0022","series-title":"Am Soc Clin Oncol","first-page":"2188","article-title":"Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors","author":"Wang","year":"2020"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0023","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0024","first-page":"2097","article-title":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin\u2019s lymphoma: a first-in-human phase I study","volume":"295","author":"Hu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0025","series-title":"A first-in-Human phase 1, multicenter, open-label study of CB-010, a next-generation CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed\/refractory b cell non-Hodgkin lymphoma (ANTLER study)","author":"O'Brien","year":"2022"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0026","first-page":"31","article-title":"Genetically engineered nanomodulators elicit potent immunity against cancer stem cells by checkpoint blockade and hypoxia relief","volume":"38","author":"Pan","year":"2024","journal-title":"Bioact Mater"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0027","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0028","article-title":"PD-1\/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism","volume":"13","author":"Dong","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0029","article-title":"PD-1\/PD-L1 axis in organ fibrosis","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0031","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3233\/BD-249006","article-title":"PD-1\/PD-L1 pathway: current research in breast cancer","volume":"43","author":"Syamsu","year":"2024","journal-title":"Breast Dis"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0033","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s40001-025-02694-1","article-title":"The PD-1\/PD-L1 pathway and Epstein-Barr virus","volume":"30","author":"Wang","year":"2025","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2021.103112","article-title":"DNA damage response and PD-1\/PD-L1 pathway in ovarian cancer","volume":"102","author":"Zhang","year":"2021","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111876","article-title":"Progress in PD-1\/PD-L1 pathway inhibitors: from biomacromolecules to small molecules","volume":"186","author":"Lin","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0036","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0037","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s12640-022-00530-6","article-title":"Circular RNA VPS18 promotes glioblastoma progression by regulating miR-1229-3p\/BCAT1 axis","volume":"40","author":"Huang","year":"2022","journal-title":"Neurotoxic Res"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004022","article-title":"CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1\/PD-L1 immunotherapy","volume":"10","author":"Xiao","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0039","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7526501","article-title":"Clinical significance of negative costimulatory molecule PD-1\/PD-L1 on peripheral blood regulatory T cell levels among patients with pulmonary tuberculosis","volume":"2022","author":"Yang","year":"2022","journal-title":"J Trop Med"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0040","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13129","article-title":"Targeting regulatory T cells in anti-PD-1\/PD-L1 cancer immunotherapy","volume":"95","author":"Zhulai","year":"2022","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0041","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5570","article-title":"Anti\u2011PD\u20111\/PD\u2011L1 and anti\u2011CTLA\u20114 associated checkpoint inhibitor pneumonitis in non\u2011small cell lung cancer: occurrence, pathogenesis and risk factors (Review)","volume":"63","author":"Hu","year":"2023","journal-title":"Int J Oncol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0042","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-associated macrophages regulate PD-1\/PD-L1 immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0044","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2022.04.018","article-title":"Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1\/PD-L1 treatment efficacy","volume":"40","author":"Long","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007068","article-title":"Discovery of a novel dual-targeting d-peptide to block CD24\/Siglec-10 and PD-1\/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy","volume":"11","author":"Shen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0046","first-page":"1556","article-title":"Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1\/PD-L1 therapies?","volume":"17","author":"Tellez","year":"2023","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0047","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00262-015-1783-4","article-title":"PD-L1-specific T cells","volume":"65","author":"Ahmad","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1328651","article-title":"Targeting the immune microenvironment for ovarian cancer therapy","volume":"14","author":"Blanc-Durand","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0049","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/eji.201344423","article-title":"PD-1 regulates extrathymic regulatory T-cell differentiation","volume":"44","author":"Chen","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0050","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0051","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0052","doi-asserted-by":"crossref","first-page":"eadl2967","DOI":"10.1126\/sciimmunol.adl2967","article-title":"NK cells restrain cytotoxic CD8(+) T cells in the submandibular gland via PD-1-PD-L1","volume":"9","author":"Borys","year":"2024","journal-title":"Sci Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0053","doi-asserted-by":"crossref","first-page":"101925","DOI":"10.1016\/j.mtbio.2025.101925","article-title":"A microfluidic tumor-on-chip platform deciphers hypoxia-driven FOXO3a\/PD-L1 signaling in gastric cancer immunotherapy resistance","volume":"33","author":"Xiang","year":"2025","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0054","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1186\/s12885-021-09009-7","article-title":"The effect of hypoxia on PD-L1 expression in bladder cancer","volume":"21","author":"Smith","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0055","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00262-025-04047-7","article-title":"Exosomal PD-L1 derived from hypoxia nasopharyngeal carcinoma cell exacerbates CD8+ T cell suppression by promoting PD-L1 upregulation in macrophages","volume":"74","author":"Yuan","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0056","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","article-title":"NAD+ metabolism maintains inducible PD-L1 expression to drive tumor immune evasion","volume":"33","author":"Lv","year":"2021","journal-title":"Cell Metabol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0057","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.7150\/jca.77619","article-title":"Clinical implications of the interaction between PD-1\/PD-L1 and PI3K\/AKT\/mTOR pathway in progression and treatment of non-small cell lung cancer","volume":"13","author":"Quan","year":"2022","journal-title":"J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1324045","article-title":"Targeting MYC at the intersection between cancer metabolism and oncoimmunology","volume":"15","author":"Venkatraman","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0059","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.3390\/ijms20174158","article-title":"Tumor metabolism as a regulator of Tumor\u2013Host interactions in the B-cell lymphoma microenvironment\u2014fueling progression and novel brakes for therapy","volume":"20","author":"Beielstein","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00005-016-0427-5","article-title":"CRISPR\/Cas9 Immune system as a tool for genome engineering","volume":"65","author":"Hryhorowicz","year":"2017","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0061","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trsl.2015.09.008","article-title":"Advances in therapeutic CRISPR\/Cas9 genome editing","volume":"168","author":"Savi\u0107","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0062","article-title":"A DNA\/upconversion nanoparticle complex enables controlled Co-delivery of CRISPR-Cas9 and photodynamic agents for synergistic cancer therapy","volume":"36","author":"Song","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0063","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.matt.2022.02.015","article-title":"Nanomaterial-mediated ablation therapy for cancer stem cells","volume":"5","author":"Pan","year":"2022","journal-title":"Matter"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0064","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41467-024-44941-9","article-title":"Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12575-022-00171-1","article-title":"CRISPR\/Cas9-mediated LINC00511 knockout strategies, increased apoptosis of breast cancer cells via suppressing antiapoptotic genes","volume":"24","author":"Azadbakht","year":"2022","journal-title":"Biologic Proc Online"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0066","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/mco2.106","article-title":"Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR\/Cas9 system in SW620\/Ad300 colorectal cancer cells","volume":"2","author":"Lei","year":"2021","journal-title":"MedComm"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0067","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.7150\/thno.72826","article-title":"CRISPR\/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells","volume":"12","author":"Tyagi","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0068","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"6","author":"Su","year":"2016","journal-title":"Scient Rep"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0069","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400068","article-title":"Genetically engineered cytomembrane nanovaccines for cancer immunotherapy","volume":"13","author":"Pan","year":"2024","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0070","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.18632\/oncotarget.23730","article-title":"CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes","volume":"9","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0071","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.imlet.2022.09.004","article-title":"Lymphopenic condition enhanced the antitumor immunity of PD-1-knockout T cells mediated by CRISPR\/Cas9 system in malignant melanoma","volume":"250","author":"Yang","year":"2022","journal-title":"Immunol Lett"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0072","first-page":"633","article-title":"Reversing T cell exhaustion by converting membrane PD-1 to its soluble form in jurkat cells; applying the CRISPR\/Cas9 exon skipping strategy","volume":"25","author":"Yousefi-Najafabadi","year":"2023","journal-title":"Cell J (Yakhteh)"},{"issue":"25","key":"10.1016\/j.seminoncol.2025.152438_bib0073","first-page":"2603","article-title":"CRISPR\/Cas9-mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"130","author":"Ren","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0074","first-page":"1","article-title":"Effect of CRISPR\/Cas9-mediated PD-1 gene knockout on proliferation, phenotype, IFN-\u03b3 and IL-2 secretion of T cells in Cynomolgus monkeys","volume":"27","author":"Yi","year":"2020","journal-title":"Chin J Cancer Biother"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000311","article-title":"Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes","volume":"8","author":"Marotte","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0076","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200626120","article-title":"Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression","volume":"120","author":"D\u00f6tsch","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0077","doi-asserted-by":"crossref","first-page":"90","DOI":"10.36401\/JIPO-22-9","article-title":"Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1\/PD-L1 immunotherapy","volume":"5","author":"Bevins","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0078","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","article-title":"Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy","volume":"24","author":"Chamberlain","year":"2022","journal-title":"Mol Ther-Oncolyt"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102484","article-title":"CRISPR\/Cas9-mediated PD-1 attenuation enhances tumor infiltrating lymphocyte-based adoptive cellular therapy in humanized-PDX model of hepatocellular carcinoma","volume":"60","author":"Ge","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40164-024-00570-y","article-title":"CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications","volume":"13","author":"Feng","year":"2024","journal-title":"Experiment Hematol Oncol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0082","unstructured":"R. Cunningham, Non-viral gold nanoparticle mediated delivery of CRISPR-Cas9 ribonucleoprotein and long DNA transgenes into primary blood cells, University of Washington; Seattle, WA, USA."},{"key":"10.1016\/j.seminoncol.2025.152438_bib0083","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4049\/jimmunol.196.Supp.214.24","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"196","author":"Rupp","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0084","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol, Immunother"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0085","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cells9040998","article-title":"Effect of CRISPR\/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth","volume":"9","author":"Nakazawa","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0086","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/hum.2017.234","article-title":"Nucleofection with plasmid DNA for CRISPR\/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells","volume":"30","author":"Hu","year":"2019","journal-title":"Human Gene Ther"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0087","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0088","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jcyt.2023.03.011","article-title":"Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness","volume":"25","author":"Lau","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0089","first-page":"1","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Scient Rep"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102010","article-title":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin\u2019s lymphoma: a first-in-human phase I study","volume":"60","author":"Hu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0091","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.53730\/ijhs.v7nS1.14397","article-title":"Enhancing the effectiveness of chimeric Antigen Receptor (CAR) T cells against tumors through CRISPR\/Cas9-mediated PD-1 disruption","volume":"7","author":"Iqbal","year":"2023","journal-title":"Int J Health Sci (Qassim)"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0092","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s12253-019-00759-1","article-title":"EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity","volume":"26","author":"Zhu","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0093","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0094","first-page":"xi12","article-title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0095","article-title":"Effect of CRISPR\/Cas9-edited PD-1\/PD-L1 on tumor immunity and immunotherapy","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0096","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.apsb.2019.07.004","article-title":"Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity","volume":"10","author":"Deng","year":"2020","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0097","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.3390\/ijms25169086","article-title":"CRISPR\/Cas-mediated knockdown of PD-L1 and KRAS in lung cancer cells","volume":"25","author":"Abounar","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0098","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/s41598-022-06430-1","article-title":"Dual-sgRNA CRISPR\/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization","volume":"12","author":"Fierro","year":"2022","journal-title":"Scient Rep"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0099","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1021\/acsami.9b23084","article-title":"Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR\/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death","volume":"12","author":"Tu","year":"2020","journal-title":"ACS Appl Mater Interf"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0100","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/cas.13958","article-title":"Programmed cell death ligand 1 d isruption by clustered regularly interspaced short palindromic repeats\/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression","volume":"110","author":"Yahata","year":"2019","journal-title":"Cancer science"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0101","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16326","article-title":"Targeting programmed cell death ligand 1 by CRISPR\/Cas9 in osteosarcoma cells","volume":"8","author":"Liao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0102","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201905751","article-title":"Dual-locking nanoparticles disrupt the PD-1\/PD-L1 pathway for efficient cancer immunotherapy","volume":"31","author":"Zhang","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0103","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41419-020-03187-1","article-title":"Engineering of \u03b1-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0104","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41417-019-0131-9","article-title":"Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout","volume":"27","author":"Zhen","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063207","article-title":"Simultaneous genetic ablation of PD-1, LAG-3, and TIM-3 in CD8 T cells delays tumor growth and improves survival outcome","volume":"23","author":"Ciraolo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0106","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.autrev.2019.02.006","article-title":"Immune checkpoints and the regulation of tolerogenicity in dendritic cells: implications for autoimmunity and immunotherapy","volume":"18","author":"Funes","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0107","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune checkpoint inhibitors: basics and challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0108","doi-asserted-by":"crossref","first-page":"CT133","DOI":"10.1158\/1538-7445.AM2018-CT133","article-title":"Abstract CT133: a phase I trial of PD-1 deficient engineered T cells with CRISPR\/Cas9 in patients with advanced non-small cell lung cancer with PD-L1 expression","volume":"78","author":"Lu","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0109","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","article-title":"CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition","volume":"15","author":"Andreu-Saumell","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2019-122374","volume":"134","author":"Stadtmauer","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0112","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.21037\/tcr-23-1146","article-title":"Application and progress of CRISPR\/Cas9 gene editing in B-cell lymphoma: a narrative review","volume":"13","author":"Jin","year":"2024","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0113","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/toxsci\/kfae003","article-title":"The development and characterization of a CRISPR\/Cas9-mediated PD-1 functional knockout rat as a tool to study idiosyncratic drug reactions","volume":"198","author":"Cho","year":"2024","journal-title":"Toxicologic Sci"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41417-019-0131-9","article-title":"Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout","volume":"27","author":"Zhen","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.seminoncol.2025.152438_bib0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2174\/0115733947263244231002042219","article-title":"Upgrading melanoma treatment: promising immunotherapies combinations in the preclinical mouse model","volume":"20","author":"Lara-Vega","year":"2024","journal-title":"Curr Cancer Ther Rev"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425001307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425001307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:14:11Z","timestamp":1773864851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775425001307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0093775425001307"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152438","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genome editing of immune checkpoints: CRISPR-mediated PD-1 inhibition in cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152438"}}